What is the NOAEL for 3,4-Dihydrocoumarin?
3,4-Dihydrocoumarin has 48 NOAEL studies in the database. The lowest reported value is 0 % via Dermal. Source: NTP ICE skin sensitization.
NOAEL Data
REACH Registered
Cosmetic Ingredient
3,4-Dihydrocoumarin
Also known as: 2H-1-Benzopyran-2-one, 3,4-dihydro-, Hydrocoumarin, 5-17-10-00013, 1,2-Benzodihydropyrone, Benzopyranone, dihydro- (+15 more)
CAS 119-84-6
3,4-Dihydrocoumarin (CAS 119-84-6) is a chemical substance. Key regulatory status: REACH registered, 4 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, ECHA REACH.
SOURCE
NOAEL studies
NOAEL studies
48
SOURCE
Chemical inventory jurisdictions
Regulatory lists
4
SOURCE
EU CLP Annex VI
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
26 fields
Name
3,4-Dihydrocoumarin
CAS Number
119-84-6
DTXSID
DTXSID2020474
Molecular Formula
C9H8O2
InChI Key
VMUXSMXIQBNMGZ-UHFFFAOYSA-N
Monoisotopic Mass
148.052429
Synonyms
2H-1-Benzopyran-2-one, 3,4-dihydro-Hydrocoumarin5-17-10-000131,2-BenzodihydropyroneBenzopyranone, dihydro-BRN 0004584Chroman, 2-oxo-Coumarin, 3,4-dihydro-Dihydrobenzopyrone3,4-DyhydrocoumarinEINECS 204-354-9FEMA No. 2381
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
5 records
DeodorizerFragranceFlavouring and nutrient
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
4 records
| List | Keyword | Source |
|---|---|---|
| banned; Europe; Personal care | European Commission | CosIng |
| Europe | European Commission | Fl@vis |
| IFRA Transparency | IFRA | IFRA |
| food_additive; Substances Added to Food (formerly EAFUS) (2/2019) | FDA | United States Food and Drug Administration (FDA) |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 48 of 48 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 531.7 | ug/mL | CD54, EC200 | Dermal | - | NTP ICE skin sensitization |
| >1037.127 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 810 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 1 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 1.9375 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 0.625 | % | Concentration, one positive response | Dermal | Human | NTP ICE skin sensitization |
| 0.8 | % | Concentration, one positive response | Dermal | Human | NTP ICE skin sensitization |
| - | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 39.7 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 19.85 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| >2000 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 3.3 | % | EC3 | Dermal | Mouse | NTP ICE skin sensitization |
| 5.6 | % | EC3 | Dermal | Mouse | NTP ICE skin sensitization |
| NM5K1Y1BT2 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| NM5K1Y1BT2 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| NM5K1Y1BT2 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| NM5K1Y1BT2 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 1 | ratio | Imax | Dermal | - | NTP ICE skin sensitization |
| 51.61 | % | Incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 100 | % | Incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 12960 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 14170 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 648 | ug/cm2 | Induction dose per skin area, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 1373 | ug/cm2 | Induction dose per skin area, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 442.9 | ug/cm2 | Induction dose per skin area, one positive response | Dermal | Human | NTP ICE skin sensitization |
| 518.4 | ug/cm2 | Induction dose per skin area, one positive response | Dermal | Human | NTP ICE skin sensitization |
| =1460 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =10 | % | LOEL | dermal | Mouse | ToxValDB ECOTOX |
| 110 | mg/kg bw/day | NOAEL | oral | rat | COSMOS DB |
| 150 | mg/kg bw/day | NOAEL | oral | dog | COSMOS DB |
| =150 | mg/kg bw/day | NOAEL | oral | Rat | EFSA |
| =150 | mg/kg bw/day | NOAEL | - | Rat | EFSA |
| 200 | mg/kg bw/day | NOAEL | oral | mouse | COSMOS DB |
| =300 | mg/kg bw/day | NOAEL | oral | Rat | EFSA |
| =300 | mg/kg bw/day | NOAEL | oral: gavage | Rat | EFSA |
| 580 | mg/kg bw/day | NOAEL | oral | rat | COSMOS DB |
| 600 | mg/kg bw/day | NOAEL | oral | rat | COSMOS DB |
| 800 | mg/kg bw/day | NOAEL | oral | mouse | COSMOS DB |
| 1000 | mg/kg bw/day | NOAEL | oral | rat | COSMOS DB |
| 1500 | mg/kg bw/day | NOAEL | oral | rat | COSMOS DB |
| 2250 | mg/kg bw/day | NOAEL | oral | mouse | COSMOS DB |
| <75 | mg/kg bw/day | NOEL | oral | Rat | ToxValDB HESS |
| 400 | mg/kg bw/day | POLY-3 lowest dose | Gavage | Mouse | NTP ICE cancer |
| 600 | mg/kg bw/day | POLY-3 lowest dose | Gavage | Rat | NTP ICE cancer |
| 2 | unitless | Relative reliability score | Dermal | Human | NTP ICE skin sensitization |
| 3 | unitless | Relative reliability score | Dermal | Human | NTP ICE skin sensitization |
| 600 | mg/kg | Top dose | Gavage | Rat | NTP ICE cancer |
| 800 | mg/kg | Top dose | Gavage | Mouse | NTP ICE cancer |
Showing 48 of 48 studies
REACH Registration
Registration status from the ECHA REACH registered substances database.
SOURCE
ECHA
1 records
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 3,4-dihydrocoumarin | 204-354-9 | ECHA overview → |
Australian Status (AICIS)
Australian industrial chemicals inventory status and applicable conditions.
SOURCE
AICIS inventory
1 records
Inventory Status
listed
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
permitted
Max
-
Category
Fragrance
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
ChEMBL / DailyMed
DIHYDROCOUMARIN
ChEMBL Phase
Not listed
Adverse Events
0
Bioactivity
2
Cannabis Data
Same-CAS cannabis compliance and lab records where available.
SOURCE
Cannabis regulatory / lab data
efsa substances
1 cannabis record found in efsa substances.
View full cannabis profile →Frequently Asked Questions
What regulatory lists include 3,4-Dihydrocoumarin?
3,4-Dihydrocoumarin appears on 4 regulatory/inventory lists including banned; Europe; Personal care, Europe, IFRA Transparency, and 1 more. Source: EPA CPDat.
Is 3,4-Dihydrocoumarin used in cosmetics?
Yes, 3,4-Dihydrocoumarin is also indexed as a cosmetic ingredient under the name Dihydrocoumarin. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for 3,4-Dihydrocoumarin come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed, cannabis regulatory/lab databases. All data traces to primary regulatory sources and is updated from official government databases.
Is 3,4-Dihydrocoumarin used outside industrial chemicals?
3,4-Dihydrocoumarin also appears in cosmetics, pharmaceutical, cannabis databases.